COMP <GO>
AXSM vs PRAX // EV/EBITDA & P/E VALUATION
Axsome Therapeutics Inc. (NASDAQ) VS. Praxis Precision Medicines Inc. (NASDAQ) • 15-METRIC TALLY: AXSM 4
— PRAX 4
■ METRIC PARITY
LAST: $136.01 (-5.83%) • MKT CAP: $7.57B
valuation
—
LAST: $273.99 (-4.18%) • MKT CAP: $7.98B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXSM VS. PRAX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXSM | PRAX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.90% | -35.00% | +13.10 | AXSM | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.25% | -3.09% | +1.84 | AXSM | /fcf-yield <GO> |
| Operating Margin | -26.10% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -28.70% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 65.50% | 8.80% | +56.70 | AXSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.34 | 26.00 | -20.66 | PRAX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 25.9 | 54.5 | -28.60 | PRAX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.91 | +0.24 | AXSM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.0x | 33.0x | +2.00 | PRAX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.57B | $7.98B | -$417.8M | PRAX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXSM REV | PRAX REV | AXSM GROSS % | PRAX GROSS % | AXSM FCF | PRAX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $638.5M | $913.4M | — | — | -$93.9M | -$249.1M |
| FY 2024 | $385.7M | $8.6M | — | — | -$128.7M | -$131.8M |
| FY 2023 | $270.6M | $2.4M | — | — | -$157.3M | -$111.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXSM // BETA 1.15
PRAX // BETA 0.91